Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,305 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06314698 | Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease | not yet recruiting | Phase 3 | 478 | RenJi HospitalOTHER | 0 | Mar 18, 2024 | clinicaltrials |
| NCT06314828 | A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL | not yet recruiting | Phase 1 | 30 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 0 | Mar 18, 2024 | clinicaltrials |
| NCT06298266 | To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma | not yet recruiting | Early Phase 1 | 15 | Guangdong Second Provincial General HospitalOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06295029 | Personalized Medication Software for BCL-2 Inhibitor in AML Patients Using Machine Learning and Genomics | not yet recruiting | — | 200 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Mar 6, 2024 | clinicaltrials |
| NCT06050941 | Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS | not yet recruiting | Phase 2 | 60 | First Affiliated Hospital of Zhejiang UniversityOTHER | 0 | Mar 5, 2024 | clinicaltrials |
| NCT06289959 | Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL | not yet recruiting | N/A | 30 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06286228 | Registry of Haploidentical Hematopoietic Stem Cell Transplantation in Adult With Hematologic Disease(Haplo) | not yet recruiting | — | 43 | Siriraj HospitalOTHER | 0 | Mar 1, 2024 | clinicaltrials |
| NCT06116929 | Hodgkin's Disease and Chemotherapy Before 40 Years(FunC-AHOD) | not yet recruiting | N/A | 63 | Lille Catholic UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06278896 | Early Neutropenic Fever De-escalation of Antibiotics Study(END) | not yet recruiting | Phase 3 | 260 | Brigham and Women's HospitalOTHER | 0 | Feb 26, 2024 | clinicaltrials |
| NCT06266975 | Chronic Kidney Disease Patient in Chronic Myloied Leukemia | not yet recruiting | — | 40 | Sahar Mohammed GadOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT06180499 | Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion(ILDTreg2) | not yet recruiting | Phase 1 / Phase 2 | 27 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Feb 14, 2024 | clinicaltrials |
| NCT06255704 | A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients(Z+RCHOP/RDHAP) | not yet recruiting | Phase 2 | 23 | Shanxi Province Cancer HospitalOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06252584 | Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients(AML-VAC-XS15) | not yet recruiting | Phase 1 | 20 | University Hospital TuebingenOTHER | 0 | Feb 9, 2024 | clinicaltrials |
| NCT06242353 | Coagulopathy in Childhood Acute Lymphoblastic Leukaemia(CoagCALL) | not yet recruiting | — | 100 | Karolinska University HospitalOTHER | 0 | Feb 5, 2024 | clinicaltrials |
| NCT06175923 | Role of BMP Pathway in MDS Progression(BMP-MDS) | not yet recruiting | — | 60 | Hospices Civils de LyonOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06175702 | Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL(LALPh2022) | not yet recruiting | — | 150 | PETHEMA FoundationOTHER | 0 | Dec 19, 2023 | clinicaltrials |
| NCT05627115 | Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma(RATiFY) | not yet recruiting | Phase 2 | 80 | University College, LondonOTHER | 0 | Nov 29, 2023 | clinicaltrials |
| NCT05979857 | Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma | not yet recruiting | Early Phase 1 | 72 | Salarius Pharmaceuticals, LLCINDUSTRY | 0 | Nov 22, 2023 | clinicaltrials |
| NCT06142188 | Relmacabtagene Autoleucel in Hematologic Malignancies | not yet recruiting | — | 150 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06133556 | Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML | not yet recruiting | Phase 2 | 237 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Nov 15, 2023 | clinicaltrials |
| NCT06097455 | First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma(CARTD-BG-1) | not yet recruiting | Early Phase 1 | 40 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT05923502 | (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) | not yet recruiting | — | 200 | Ruijin HospitalOTHER | 0 | Oct 23, 2023 | clinicaltrials |
| NCT06075238 | Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT | not yet recruiting | Phase 2 | 68 | Sichuan UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06070246 | Navigating the Clinical Research Process for Lymphoma | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT04790045 | Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens(LymBIO) | not yet recruiting | Phase 4 | 30 | Paolo GhiaOTHER | 0 | Oct 3, 2023 | clinicaltrials |
| NCT06049472 | Patient Perspectives in Mantle Cell Lymphoma Clinical Research | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06049485 | Assessing the Experience of Patients Undergoing Follicular Lymphoma Clinical Research | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06022341 | MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic Strategies(MOZART) | not yet recruiting | N/A | 120 | University Hospital, AngersOTHER_GOV | 0 | Sep 1, 2023 | clinicaltrials |
| NCT05875649 | A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure(CLAG) | not yet recruiting | — | 137 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05931757 | A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL | not yet recruiting | Phase 2 | 22 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05909826 | Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM(KMM-KCd) | not yet recruiting | Phase 2 | 49 | Dong-A University HospitalOTHER | 0 | Jun 18, 2023 | clinicaltrials |
| NCT05814848 | A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma | not yet recruiting | Phase 4 | 13 | Changhai HospitalOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT05876832 | A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) | not yet recruiting | Phase 3 | 312 | Shijiazhuang Yiling Pharmaceutical Co. LtdINDUSTRY | 0 | May 26, 2023 | clinicaltrials |
| NCT03969693 | Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation | not yet recruiting | — | 50 | Chang Gung Memorial HospitalOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05746858 | Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIMOSA)(MIMOSA) | not yet recruiting | — | 300 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05681403 | Clinical Study of Improved BEAM Conditioning Regimen for ASCT in Lymphoma | not yet recruiting | N/A | 53 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT05602168 | Collection of Sequential Samples From Patients With Malignant Myeloid Hemopathy for the Study of Treatment Resistance | not yet recruiting | N/A | 400 | Institut Paoli-CalmettesOTHER | 0 | Nov 1, 2022 | clinicaltrials |
| NCT05581875 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory | not yet recruiting | Phase 1 / Phase 2 | 48 | Hellenic Society of HematologyOTHER | 0 | Oct 17, 2022 | clinicaltrials |
| NCT05440747 | Treatment Free Remission (TFR) in CML Patients （CML-CP）Study | not yet recruiting | — | 203 | Guangdong Provincial People's HospitalOTHER | 0 | Jul 1, 2022 | clinicaltrials |
| NCT05429515 | Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury | not yet recruiting | Phase 4 | 50 | Peking Union Medical College HospitalOTHER | 0 | Jun 23, 2022 | clinicaltrials |
| NCT05367765 | A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | not yet recruiting | Phase 4 | 2,400 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 10, 2022 | clinicaltrials |
| NCT05353907 | Dual-Energy Computed Tomography for Improving Imaging Assessment of Multiple Myeloma(DECIMA) | not yet recruiting | — | 78 | Guy's and St Thomas' NHS Foundation TrustOTHER | 0 | Apr 29, 2022 | clinicaltrials |
| NCT05347641 | Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma | not yet recruiting | Phase 2 | 23 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Apr 26, 2022 | clinicaltrials |
| NCT05298293 | Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma(EMILY) | not yet recruiting | N/A | 160 | WepromOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT05280626 | First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP | not yet recruiting | Phase 2 | 100 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 0 | Mar 15, 2022 | clinicaltrials |
| NCT05205902 | TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides(TOTEM-01) | not yet recruiting | Phase 3 | 78 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jan 25, 2022 | clinicaltrials |
| NCT05181501 | A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2) | not yet recruiting | Phase 1 | 20 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 6, 2022 | clinicaltrials |
| NCT05161026 | Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry(REMODALLO) | not yet recruiting | N/A | 120 | University Hospital, CaenOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT05091541 | A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 125 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 0 | Oct 25, 2021 | clinicaltrials |
| NCT05054231 | Immunological Profile for Patients Treated With CAR-T Cells(SI-CART) | not yet recruiting | N/A | 500 | Institut Paoli-CalmettesOTHER | 1 | Oct 15, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Mar 18, 2024source: clinicaltrials